New research indicates that people who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end traditional diet and exercise programs.
Findings released in a leading medical journal demonstrates that while obese people can lose a large proportion of their total mass while using the jabs, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Individuals using these treatments must be aware of the potential of quick weight regain when the medication concludes," warns researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to original mass within about a year and a half.
Comparing Treatments
The analysis, which examined dozens of trials involving over 9,000 of patients, contrasted the effects of the injectable medications with older methods.
The team note that individuals who shed pounds through dieting typically experience a more gradual weight regain—approximately 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Nutrition scientists propose the way of the drugs accounts for the heightened weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating much more probable."
An Ongoing Disease?
Medical guidelines suggest the jabs for individuals with obesity-related health risks, accompanied by recommended lifestyle changes.
A number of clinicians say that, considering the significant potential of relapse, the therapy should be considered long-term.
This view is reinforced by pharmaceutical companies, who say that the results "underscore the persistent character of obesity," akin to managing diseases like hypertension.
Patient Testimonies
People who have stopped the jabs explain a powerful return of cravings.
"It felt as if a trigger that goes on and you become ravenous," recalled one woman.
This challenge is worsened if individuals have not established lasting lifestyle or habit changes during therapy.
Significant Adoption
Figures suggest that millions of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is more common among women than men.
- The middle-aged demographic shows the highest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
Finally, researchers emphasize that while these medications are potent tools for shedding pounds, they are not a standalone fix and maintained weight loss likely depends on combined lifestyle support.
